IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection

Abstract

IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.

Keywords

• il-15
• radiotherapy
• dendritic cells
• interferon type 1
• cd8 t-cells